Phathom Pharmaceuticals, Inc. (PHAT) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Florham Park, NJ, United States. The current CEO is Steven L. Basta.
PHAT has IPO date of 2019-10-25, 427 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $998.38M.
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
